New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Cited 2 time in webofscience Cited 0 time in scopus
  • Hit : 98
  • Download : 0
The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. Although, these results are encouraging, many patients do not respond to, or rapidly recur after, current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion, is a snapshot of the current biomarker and clinical trial landscapes for SCLC. Finally, we identify key knowledge gaps that should be addressed to advance the field in pursuit of reduced SCLC mortality. This review largely summarizes work presented at the Third Biennial International Association for the Study of Lung Cancer SCLC Meeting. (C) 2020 International Association for the Study of Lung Cancer.
Publisher
ELSEVIER SCIENCE INC
Issue Date
2020-04
Language
English
Article Type
Review
Citation

JOURNAL OF THORACIC ONCOLOGY, v.15, no.4, pp.520 - 540

ISSN
1556-0864
DOI
10.1016/j.jtho.2020.01.016
URI
http://hdl.handle.net/10203/273974
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 2 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0